Key Takeaways:
Oxford-based Scancell is taking its melanoma immunotherapy to a US audience through an all-share merger with Neuphoria Therapeutics and an $89 million financing package.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) agreed to acquire Neuphoria Therapeutics in an all-share transaction that will give the combined company a dual listing on Nasdaq and London's AIM market. Existing Scancell shareholders will own 85.5% of the enlarged group on a pro forma basis, with Neuphoria holders taking 14.5% through American Depositary Shares and contingent value rights tied to Neuphoria's partnered assets.
"The transaction will establish Scancell on Nasdaq and enables access to US investors and the broader US life sciences sector for the capital we need to execute the registrational Phase 3 study for iSCIB1+ in advanced melanoma," Chief Executive Officer Dr Phil L'Huillier said.
The financing comprises a $39.1 million private placement from new and existing shareholders, a UK placing expected to raise about $12 million, a retail offer of up to $3 million, and a non-binding term sheet with funds managed by BlackRock for debt financing of up to $25 million. Neuphoria's cash balances will contribute at least $10 million, giving the combined company a pro forma net cash position of approximately $79.1 million.
The iSCIB1+ Data That Made This Possible
The deal's centerpiece is iSCIB1+, an off-the-shelf DNA ImmunoBody designed to train the immune system to attack tumor cells. Data from the Phase 2 SCOPE study showed 77% progression-free survival at 22 months when combined with the checkpoint inhibitors ipilimumab and nivolumab — a result that earned fast-track designation from the US Food and Drug Administration. Further progression-free and overall survival data from the same study are expected within the next 12 months.
The financing is structured to carry the global registrational Phase 3 trial through its primary readout in the second half of 2028 and extend the group's cash runway into 2029. For context, the standard of care in advanced melanoma — checkpoint inhibitor combinations — typically shows median progression-free survival of 11.5 months in first-line treatment, per published clinical benchmarks.
What Neuphoria Brings to the Deal
Neuphoria, a Nasdaq-listed biotech focused on neuropsychiatric disorders, saw its lead candidate BNC210 miss primary and secondary endpoints in a Phase 3 PTSD trial in October 2025 and has since halted development in social anxiety disorder. The company had $19.4 million in cash as of March 2026. Scancell does not intend to develop Neuphoria's non-partnered assets beyond maintaining key intellectual property, instead focusing on its own oncology pipeline.
Neuphoria Chairman Alan Fisher said the deal lets his shareholders "participate in the future value creation of Scancell's differentiated oncology pipeline, while preserving potential upside from Neuphoria's partnered assets through the CVRs."
The Strategic Logic
For Scancell, the transaction solves a structural problem facing many UK-listed biotechs: limited access to the deep capital pools of US life sciences investors. A Nasdaq listing under the ticker SCLT, alongside its existing AIM quotation, opens the door to institutional investors that typically avoid London's junior market. The 10-for-1 share consolidation planned before closing is designed to align the ADS price with US market expectations.
Completion is expected in late Q4 2026, subject to shareholder votes from both companies, Nasdaq and AIM admissions, and SEC review of the Form F-4 registration statement. Both boards have approved the transaction unanimously.
Scancell shares trade on AIM with a market capitalization of approximately £140 million. The company's pipeline also includes Modi-1, a Moditope peptide in Phase 2 for head and neck and renal cancers, and GlyMab antibodies licensed to Genmab. The combined entity will have a clearer financial runway than most AIM-listed biotechs, but the Phase 3 readout in 2028 remains the single most important catalyst for valuation.
This article is for informational purposes only and does not constitute investment advice.
